A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

2024-513199-16-00 Protocol 89853413AML1001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 4 Feb 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites · Protocol 89853413AML1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 100
Countries 1
Sites 3

Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Feb 2025 → ongoing
Decision date (initial)
2025-01-20
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

VersionLevelCodeTermSystem organ class
27.0 PT 10028533 Myelodysplastic syndrome 100000004864
21.1 LLT 10081514 Acute myeloid leukemia refractory 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 20 3
Rest of world
United States, United Kingdom, Canada
80

Investigational sites

Spain

3 sites · Ongoing, recruiting
Hospital Universitario Fundacion Jimenez Diaz
Hematology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Clinica Universidad De Navarra
Hematology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Clinic De Barcelona
Hematology, Calle Villarroel 170, 08036, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-02-04 2025-02-04

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-07 Spain Acceptable
2025-01-20
2025-01-20
2 SUBSTANTIAL MODIFICATION SM-1 2025-03-04 Spain Acceptable
2025-03-17
2025-03-17
3 SUBSTANTIAL MODIFICATION SM-2 2025-10-09 Spain Acceptable
2026-01-29
2026-02-03